Evidence map›Paper›PMID 28750675›Full record

ArticleAlzheimer's research & therapy2017

Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer's disease core biomarkers in Lewy body disorders and Alzheimer's dementia.

Davide Chiasserini, Leonardo Biscetti, Paolo Eusebi, Nicola Salvadori, Giulia Frattini, Simone Simoni, Naomi De Roeck, Nicola Tambasco, Erik Stoops, Hugo Vanderstichele and 4 more

Open access · goldAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's research & therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers.

0numbers the graph read from it
0cells of the map it votes in
61citing papers in PubMed
12.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

61 citing papers in PubMed, 143 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. The Role of α-Synuclein in Etiology of Neurodegenerative Diseases.International journal of molecular sciences · 2024
    Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article

1 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 7 institutions in 3 countries.

Davide ChiasseriniSection of Neurology, Department of Medicine, University of Perugia, Perugia, Italy. d.chiasserini@vumc.nl.
Leonardo BiscettiSection of Neurology, Department of Medicine, University of Perugia, Perugia, Italy.
Paolo EusebiSection of Neurology, Department of Medicine, University of Perugia, Perugia, Italy.
Nicola SalvadoriSection of Neurology, Department of Medicine, University of Perugia, Perugia, Italy.
Giulia FrattiniSection of Neurology, Department of Medicine, University of Perugia, Perugia, Italy.
Simone SimoniNeurology Clinic, University Hospital S. Maria della Misericordia - University of Perugia, Perugia, Italy.
Naomi De RoeckReference Center for Biological Markers of Dementia (BIODEM), Institute Born-Bunge, University of Antwerp, Antwerp, Belgium.
Nicola TambascoNeurology Clinic, University Hospital S. Maria della Misericordia - University of Perugia, Perugia, Italy.
Erik StoopsADx NeuroSciences, Technologiepark 4, 9052, Gent, Belgium.
Hugo VandersticheleADx NeuroSciences, Technologiepark 4, 9052, Gent, Belgium.
Sebastiaan EngelborghsReference Center for Biological Markers of Dementia (BIODEM), Institute Born-Bunge, University of Antwerp, Antwerp, Belgium.
Brit MollenhauerDepartment of Neurosurgery and Institute of Neuropathology, University Medicine Göttingen, Robert-Koch-Str. 40, 37075, Göttingen, Germany.
Paolo CalabresiSection of Neurology, Department of Medicine, University of Perugia, Perugia, Italy.
Lucilla ParnettiSection of Neurology, Department of Medicine, University of Perugia, Perugia, Italy.
University of Perugia · ITAblynx (Belgium) · BEADx NeuroSciencesFondazione Santa Lucia · ITParacelsus Elena Klinik Kassel · DEUniversity of Antwerp · BEZNA Middelheim Hospital · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNeurodegenerative disorders such as Alzheimer's disease (AD), Parkinson's disease with dementia (PDD), and dementia with Lewy bodies (DLB) share clinical and molecular features. Cerebrospinal fluid (CSF) biomarkers may help the characterization of these diseases, improving the differential diagnosis. We evaluated the diagnostic performance of five CSF biomarkers across a well-characterized cohort of patients diagnosed with AD, DLB, PDD, and Parkinson's disease (PD).

methodsA total of 208 patients were enrolled in 3 European centers. The diagnostic groups (AD, n = 48; DLB, n = 40; PDD, n = 20; PD, n = 54) were compared with cognitively healthy neurological control subjects (patients with other neurological diseases [OND], n = 46). CSF levels of fatty acid binding protein 3, heart type (FABP3), α-synuclein (α-syn), amyloid-β peptide 1-42, total tau (t-tau), and phosphorylated tau 181 (p-tau) were assessed with immunoassays. Univariate and multivariate statistical analyses were applied to calculate the diagnostic value of the biomarkers as well as their association with clinical scores.

resultsFABP3 levels were significantly increased in patients with AD and DLB compared with those with PD and OND (p < 0.001). CSF t-tau, p-tau, and α-syn were significantly higher in patients with AD than in patients with PDD, DLB, PD, and OND. Combination of FABP3 with p-tau showed high accuracy for the differential diagnosis between AD and DLB (AUC 0.92), whereas patients with AD were separated from those with PDD using a combination of p-tau, FABP3, and α-syn (AUC 0.96). CSF FABP3 was inversely associated with Mini Mental State Examination score in the whole cohort (r = -0.42, p < 0.001).

conclusionsThe combination of CSF biomarkers linked to different aspects of neurodegeneration, such as FABP3, α-syn, and AD biomarkers, improves the biochemical characterization of AD and Lewy body disorders.

Indexed as

AgedAged, 80 and overAge Factorsalpha-SynucleinAlzheimer DiseaseAmyloid beta-PeptidesArea Under CurveDiagnosis, DifferentialEuropeFatty Acid Binding Protein 3FemaleHumansImmunoassayLewy Body DiseaseMaleMental Status and Dementia Testsalpha-SynucleinAmyloid beta-Peptidesamyloid beta-protein (1-42)Fatty Acid Binding Protein 3Peptide Fragmentstau ProteinsAmyloidBiomarkersCerebrospinal fluidDementiaHeart fatty acid binding proteinTauα-Synuclein

Identifiers

PMID28750675
PMCPMC5532764
OpenAlexW2739934261

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.